Pages that link to "Q71234850"
Jump to navigation
Jump to search
The following pages link to Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity (Q71234850):
Displaying 50 items.
- Intravenous immunoglobulin for myasthenia gravis (Q24202443) (← links)
- Treatment for Lambert-Eaton myasthenic syndrome (Q24234103) (← links)
- Intravenous immunoglobulin for myasthenia gravis (Q24242078) (← links)
- Immunosuppressive agents for myasthenia gravis (Q24243208) (← links)
- Corticosteroids for myasthenia gravis (Q24244116) (← links)
- Immunosuppressive agents for myasthenia gravis (Q24244754) (← links)
- Intravenous immunoglobulin for myasthenia gravis (Q24246185) (← links)
- Treatment for Lambert-Eaton myasthenic syndrome (Q24246913) (← links)
- Treatment for Lambert-Eaton myasthenic syndrome (Q24248823) (← links)
- Amphipathic segment of the nicotinic receptor alpha subunit contains epitopes recognized by T lymphocytes in myasthenia gravis (Q24561626) (← links)
- Thymectomy and azathioprine have no effect on the phenotype of CD4 T lymphocyte subsets in myasthenia gravis (Q33590421) (← links)
- Familial autoimmune myasthenia gravis with different pathogenetic antibodies (Q33631009) (← links)
- A conceptual framework for evaluating impairments in myasthenia gravis (Q33638581) (← links)
- Immunoadsorption therapy for myasthenia gravis (Q33732456) (← links)
- Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects (Q34131386) (← links)
- T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits (Q34172481) (← links)
- Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor alpha subunit (Q34334721) (← links)
- Review: Progress in the treatment of myasthenia gravis (Q34409088) (← links)
- The role of antibodies in myasthenia gravis (Q34831033) (← links)
- Long-term respiratory muscle endurance training in patients with myasthenia gravis: first results after four months of training (Q35176420) (← links)
- The features of myasthenia gravis with autoantibodies to MuSK. (Q35489482) (← links)
- Effect of Gender, Disease Duration and Treatment on Muscle Strength in Myasthenia Gravis (Q36163640) (← links)
- Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study (Q36228181) (← links)
- Muscle autoantibodies in myasthenia gravis: beyond diagnosis? (Q36420763) (← links)
- Myasthenia Gravis: Prototype of the Antireceptor Autoimmune Diseases (Q36635317) (← links)
- Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration (Q37027684) (← links)
- The immunopathogenesis of myasthenia gravis (Q37218062) (← links)
- Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale (Q37589680) (← links)
- Immunopathologic events at the endplate in myasthenia gravis (Q38153563) (← links)
- Myasthenia gravis: An autoimmune response against the acetylcholine receptor (Q40487612) (← links)
- Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy (Q42063287) (← links)
- Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: Results of a prospective multicenter open-label trial (Q42955589) (← links)
- Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient. (Q43916530) (← links)
- Standards of Measurements in Myasthenia Gravis (Q44552451) (← links)
- Clinical study of fk506 in patients with myasthenia gravis (Q44627080) (← links)
- Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis (Q44672927) (← links)
- Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients (Q44756497) (← links)
- "Seronegative" myasthenia with antibodies against muscle-specific tyrosine-kinase (Q44813150) (← links)
- Widely varying TNF-alpha levels in patients with myasthenia gravis (Q46123333) (← links)
- Fiberoptic endoscopic evaluation of swallowing with simultaneous Tensilon application in diagnosis and therapy of myasthenia gravis. (Q46793494) (← links)
- T-cell interleukin-6 receptor binding in patients with myasthenia gravis (Q47692804) (← links)
- Synthesis of anti-acetylcholine receptor antibodies by CD5- B cells from peripheral blood of myasthenia gravis patients (Q48787660) (← links)
- Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial). (Q50033604) (← links)
- Standards of measurements in myasthenia gravis. (Q52956433) (← links)
- Both binding and blocking antibodies correlate with disease severity in myasthenia gravis. (Q53510950) (← links)
- Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy. (Q54293402) (← links)
- Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis (Q58576008) (← links)
- Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial (Q64229599) (← links)
- Spleen cell dialyzable extracts (SCDE) mediated immunotherapy for patients with myasthenia gravis (Q67802632) (← links)
- Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis (Q67977337) (← links)